Scott Ericksen Sells 1,500 Shares of Illumina (NASDAQ:ILMN) Stock

Illumina, Inc. (NASDAQ:ILMN) CAO Scott Ericksen sold 1,500 shares of Illumina stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $150.10, for a total value of $225,150.00. Following the completion of the transaction, the chief accounting officer directly owned 14,946 shares in the company, valued at approximately $2,243,394.60. This represents a 9.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Illumina Trading Up 0.9%

ILMN stock traded up $1.44 during trading on Monday, hitting $164.40. The company had a trading volume of 2,190,365 shares, compared to its average volume of 1,870,274. The stock has a market cap of $24.87 billion, a PE ratio of 29.89, a PEG ratio of 2.70 and a beta of 1.50. The business has a 50-day moving average of $133.73 and a 200-day moving average of $132.09. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. Illumina, Inc. has a one year low of $78.79 and a one year high of $165.97.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.10. The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The company’s revenue was up 4.8% compared to the same quarter last year. During the same quarter last year, the business earned $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Research analysts predict that Illumina, Inc. will post 5.2 earnings per share for the current fiscal year.

Institutional Trading of Illumina

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Glenmede Trust Co. NA boosted its position in shares of Illumina by 6.5% during the first quarter. Glenmede Trust Co. NA now owns 2,288 shares of the life sciences company’s stock valued at $282,000 after buying an additional 140 shares during the last quarter. Groupama Asset Managment raised its position in Illumina by 3.7% in the 1st quarter. Groupama Asset Managment now owns 9,545 shares of the life sciences company’s stock valued at $1,177,000 after buying an additional 340 shares during the last quarter. Janus Henderson Group PLC lifted its stake in Illumina by 1.4% during the 1st quarter. Janus Henderson Group PLC now owns 2,100,638 shares of the life sciences company’s stock valued at $258,924,000 after acquiring an additional 29,094 shares in the last quarter. Bull Harbor Capital LLC bought a new position in Illumina during the 1st quarter valued at $1,413,000. Finally, Arkadios Wealth Advisors boosted its holdings in Illumina by 1.6% during the 1st quarter. Arkadios Wealth Advisors now owns 8,001 shares of the life sciences company’s stock worth $986,000 after acquiring an additional 124 shares during the last quarter. 89.42% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on ILMN shares. Barclays boosted their target price on shares of Illumina from $110.00 to $122.00 and gave the company an “underweight” rating in a report on Friday, May 1st. Weiss Ratings lowered Illumina from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, April 29th. Evercore reissued an “outperform” rating on shares of Illumina in a research note on Friday, May 1st. Guggenheim upped their target price on Illumina from $170.00 to $180.00 and gave the company a “buy” rating in a research report on Monday. Finally, Royal Bank Of Canada assumed coverage on Illumina in a research note on Thursday, May 14th. They set an “outperform” rating and a $170.00 target price for the company. Seven equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $138.38.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.